PRTA•benzinga•
Why Is Prothena Stock Trading Lower On Tuesday?
Summary
Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and new focus expected.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 27, 2025 by benzinga